A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Bold Therapeutics, Inc.
IMGT Co., Ltd.
Taiho Oncology, Inc.
Tyligand Pharmaceuticals (Suzhou) Limited
Revolution Medicines, Inc.
DEKA Biosciences
Ono Pharmaceutical Co. Ltd
Akeso
ImmunityBio, Inc.
Eli Lilly and Company
Ono Pharmaceutical Co. Ltd
ImmunityBio, Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.
ImmunityBio, Inc.
ImmunityBio, Inc.
Sumitomo Pharma America, Inc.
MedImmune LLC
Ipsen
Eli Lilly and Company
Gilead Sciences
Lumos Pharma
Lumos Pharma
TG Therapeutics, Inc.
Eli Lilly and Company
Leaf Vertical Inc.
Sanofi
Sanofi
Eli Lilly and Company